Does Opium Consumption Have Shared Impact on Atherosclerotic Cardiovascular Disease and Cancer?

Farzad Masoudkabir, MD1, 2; Reza Malekzadeh, MD3; Negin Yavari, MD1; Kazem Zendehdel, MD, PhD4; Arya Mani, MD5; Ali Vasheghani-Farahani, MD6; Andrew Ignaaszewski, MD6; Mustafa Toma, MD, PhD7; Pegah Roayaei, MD5; Karam Turk-Adawi, PhD5; Nizal Sarrafzadegan, MD8, 9*

1Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
2Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
3Digestive Disease Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
4Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
5Yale Cardiovascular Genetics Program, Yale Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
6Division of Cardiology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
7QU Health, College of Health Science, Qatar University, Al Jamiaa St, Doha, Qatar
8Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
9School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Abstract

Although atherosclerotic cardiovascular disease (ASCVD) and cancer are seemingly different types of disease, they have multiple shared underlying mechanisms and lifestyle-related risk factors like smoking, unhealthy diet, excessive alcohol consumption, and inadequate physical activity. Opium abuse is prevalent in developing countries, especially the Middle East region and many Asian countries. Besides recreational purposes, many people use opium based on a traditional belief that opium consumption may confer protection against heart attack and improve the control of the risk factors of ASCVD such as diabetes mellitus, hypertension, and dyslipidemia. However, scientific reports indicate an increased risk of ASCVD and poor control of ASCVD risk factors among opium abusers compared with nonusers. Moreover, there is accumulating evidence that opium consumption exerts potential carcinogenic effects and increases the risk of developing various types of cancer. We conducted a review of the literature to review the current evidence on the relationship between opium consumption and ASCVD as well as various kinds of cancer. In addition, we will discuss the potential shared pathophysiologic mechanisms underlying the association between opium abuse and both ASCVD and cancer.

Keywords: Atherosclerosis, Cancer, Coronary artery disease, Opium, Tumor

Cite this article as: Masoudkabir F, Malekzadeh R, Yavari N, Zendehdel K, Mani A, Vasheghani-Farahani A, et al. Does opium consumption have shared impact on atherosclerotic cardiovascular disease and cancer? Arch Iran Med. 2022; 25(1):50-63. doi: 10.34172/aim.2022.08

Received: October 21, 2020, Accepted: July 7, 2021, ePublished: January 1, 2022

Introduction

Atherosclerotic cardiovascular disease (ASCVD) and cancer are the two main causes of mortality and morbidity globally, accounting for two-thirds of all deaths in 2012.2,3 The occurrence of ASCVD and cancer is rising in all socioeconomic classes throughout the world over due to population aging and changes in the distribution of major lifestyle-related risk factors. Although globally, there are 4 major shared risk factors for ASCVD and cancer (viz, unhealthy diet, sedentary lifestyle, chronic alcohol and tobacco consumption), there may be local or regional habits that may significantly contribute to the increasing burden of both ASCVD and cancer.1, 4–6 The importance of common adjustable risk factors for both ASCVD and cancer is redirected in our understanding of the mutual genetics and molecular mechanisms that are essential to the pathogenesis of both diseases.7 Moreover, modifiable risk factors are promising targets for joint preventive efforts against ASCVD and cancer.8

The United Nations Office of Drugs and Crime (UNODC) estimates that in 2019, almost 30 million people consumed opium or its derivatives illegally around the globe.9 Very recently, opium consumption was classified into Group I as carcinogenic by the International Agency for Research on Cancer (IARC).10 While opium use and availability in developed countries have decreased over the years, opium is still the most regularly abused substance after tobacco, in developing countries such as the Middle East region, and many Asian countries.11, 12 In addition to availability, another reason for the high consumption of opium in these countries could be a traditional belief among Eastern people and even medical staff that opium consumption may have beneficial effects on health, particularly ASCVD as well as other cardiovascular risk...
Shared Impact of Opium on ASCVD and Cancer

Factors including diabetes mellitus, hypertension, and dyslipidemia. In the recent decade, numerous studies have been presented on humans and animals to evaluate the effect/association of opium consumption on/with various health outcomes. Previously, we have reviewed the shared pathophysiologic pathways of ASCVD and cancer to show that these two are unexpectedly similar to each other. In this narrative review, we will review the available evidence on the relationship between opium consumption and ASCVD as well as various kinds of cancer. Additionally, we will discuss the potential shared pathophysiologic mechanisms underlying the association between opium abuse and both ASCVD and cancer.

Association between Opium Consumption and ASCVD

There is a traditional belief among Asians that opium consumption may exert a beneficial effect on the cardiovascular system such as preventing heart attacks. During the past 15 years, many observational studies have been conducted to evaluate such beliefs, and they have found interesting results. We will separately review the studies on the association between opium consumption and each of stable coronary artery disease (CAD), acute coronary syndromes, and the outcomes of coronary revascularization.

Stable Coronary Artery Disease

Clinical Studies

The paucity of studies on mortality and morbidity among opium users has prompted scientists to conduct research on individuals with opium consumption and its relationship with ASCVD. A cross-sectional study by Sadeghian and colleagues on 2405 patients demonstrated that after adjustment for cardiac risk factors, opium consumption was significantly associated with the presence of CAD (odds ratio [OR] = 1.8, 95% confidence interval [CI] = 1.1 to 3.1; P = 0.015), and a dose-response relationship was observed between the dosage of opium consumption and the severity of CAD. In another cross-sectional study, which investigated the predictors of premature CAD in the Iranian population, Sadeghian and colleagues found that high prevalence of opium consumption was the most important risk factor for premature CAD in male patients (OR = 4.47, 95% CI = 1.49 to 13.38; P < 0.01). In another cross-sectional study, Hosseini et al evaluated 2874 opium consumers compared with 2568 non-consumers and found that opium use was an independent risk factor for CAD (OR = 1.31, 95% CI = 1.01 to 1.69; P = 0.042). Darabad and colleagues conducted a survey on 1170 patients, including 121 opium-using patients, who underwent coronary angiography. They showed that opium addiction was associated with angiographically confirmed CAD. Nonetheless, they did not find any significant association between opium use and the number of affected coronary vessels.

In addition to atherosclerotic disease of the major epicardial coronary arteries, it has been shown that opium use is related with microvascular coronary dysfunction (MCD). In a cross-sectional study on 250 Iranian patients with confirmed ischemic heart disease by exercise test and coronary angiography, Nadimi et al observed that opium addiction was the only factor associated with MCD (OR = 3.57, 95% CI = 1.42 to 9.02, P = 0.0069).

There are other several studies on the association between opium consumption and CAD occurrence that have shown an increased risk of CAD in association with opium use. One exception is an investigation by Rezvani et al who showed no significant association between opium consumption and ischemic heart disease.

A summary of studies on the association between opium consumption and stable CAD and its outcomes is presented in Table 1.

Acute Coronary Syndromes

Despite consistency in the findings of studies evaluating the association between opium consumption and stable CAD, there is controversy among investigations regarding the possible association between opium consumption and the occurrence of acute MI and its short- and medium-term outcomes such as prolonged hospitalization, atrial fibrillation, and heart failure. In a cross-sectional research, which was followed by a 1-year longitudinal cohort study on 690 patients with acute myocardial infarction (AMI), Roohafza and colleagues investigated the prevalence of opium dependency and the occurrence of short- and long-term events following AMI. They found that out of the 690 patients, 118 were opium-dependent. Opium dependency decreased age by 3.6 years (95% CI = 1.2 to 6.0; P = 0.003) for the occurrence of post-MI mortality and morbidity independent of cigarette smoking. Harati et al observed that those with opium dependency had almost significantly higher in-hospital mortality (11.5% vs 5.9%; P = 0.072) and significantly higher rehospitalization rates (38.5% vs 13.7%; P < 0.001). Currently, many physicians do not advise their patients to quit opium consumption because of the fear of inducing a heart attack. Masoomi and colleagues conducted a remarkable study to evaluate whether opium withdrawal was a trigger for AMI. They evaluated 81 patients who had discontinued opium consumption and observed that after adjustments for demographic characteristics, marital status, education level, and common CAD risk profiles, opium withdrawal was not a trigger for AMI (OR = 0.920, 95% CI = 0.34 to 2.42; P = 0.866). Dehghani et al also demonstrated that in-hospital mortality was not significantly different between 239 opium-addicted patients and 221 nonaddicted patients. Opium addiction was associated with lower occurrence of anterior wall MI (26.4% vs 36.4% in nonaddicted patients) and its related early mortality. Recently, a systematic review and meta-analysis by Nakhaee et al evaluated the association between opium and CVD. They demonstrated a significant association between opium use and CAD but not in-hospital mortality (OR = 2.75, 95% CI = 2.04 to 3.75; I² = 47% vs OR = 1.44, 95% CI = 0.88 to 2.36; I² = 51%).
Arch Iran Med, Volume 25, Issue 1, January 2022

Cross-sectional Study Population

97.3% of opium users (222 out of 228) were using opium for ≥ 12 months (unpublished data).

Severity of Opium

Opium use

Results

β

Cross-sectional

Cross-sectional

Cross-sectional

Cohort

N = 940 (387 men and 553 women)

Opium was an independent risk factor for CAD in non-cigarette smoking cases (OR = 3.575, 95% CI = 1.42 to 9.02; P = 0.0069).

N = 558 (161 opium users and 397 nonusers)

No association was found between opium consumption and ischemic heart disease.

N = 5442 (2874 opium users and 2568 nonusers)

Opium was an independent risk factor for CAD (OR = 1.31, 95% CI = 1.01 to 1.69; P = 0.042).

N = 50045 (8487 opium users and 41558 nonusers)

Increased risks of all-cause mortality were reported in opium users (adjusted HR = 1.86; 95% CI = 1.68 to 2.06).

N = 1170 (121 opium-dependent cases and 1049 nonusers)

Opium dependence was independently associated with the presence of CAD (OR = 2.08; P = 0.019).

N = 250 (125 patients with MCD and 125 individuals for comparison)

Opium addiction was an independent predictor of MCD (OR = 3.575, 95% CI = 1.42 to 9.02; P = 0.0069).

There are a few studies that have indicated no association between opium consumption and the increased incidence of MI or in-hospital mortality. Still, vis-à-vis the effects of opium on the cardiovascular system, there is always the presence of such intervening factors as the dose of drugs and the length and frequency of opium use, which should be considered. Additionally, research should take into account different routes of drug administration (e.g. inhalation, oral use, and injection), for which opium absorption and blood levels are different.

The association between opium consumption and acute coronary syndromes and the related outcomes is demonstrated in Table 2.

Table 1. Summary of Studies Evaluating the Association Between Opium Consumption and Stable Coronary Artery Disease and its Outcomes

| Study Reference | Type of Study | Severity of Opium Consumption | Study Population | Results |
|-----------------|--------------|-------------------------------|------------------|---------|
| Sadeghian et al, 2007 | Cross-sectional | Use of opium ≥ 1 time in life | N = 2405 (322 opium users and 2083 nonusers) | A higher presence of CAD was observed in opium users than in nonusers (OR = 1.8, 95% CI = 1.1 to 3.1; P = 0.015). A significant dose-response relationship was detected between the dose of opium consumption and the severity of CAD based on the clinical vessel score (r = 0.2). |
| Masoomi et al, 2010 | Cross-sectional | Addiction | N = 299 (118 opium addicts and 181 nonusers) | After adjustments for potential confounders, patients who frequently consumed opium were more expected to have severe CAD (OR = 1.82, 95% CI = 0.93 to 3.56; P = 0.08). |
| Masoomi et al, 2010 | Cross-sectional | Addiction | N = 91 (58 patients with CAD and 33 cases of normal coronary arteries) | Opium addiction was an independent risk factor for CAD in non-cigarette smoking cases (OR = 3.575, 95% CI = 1.42 to 9.02; P = 0.0069). |
| Sadeghian et al, 2010 | Cross-sectional | Opium use | N = 940 (387 men aged < 45 y) | Opium usage was the most important risk factor for CAD in male patients younger than 45 years in Iranian sample (OR = 4.4, 95% CI: 1.49 to 13.18; P < 0.01). |
| Hosseini et al, 2011 | Cross-sectional | Use of opium for ≥ 3 mon | N = 456 (228 opium-using diabetic patients and 228 non-opium-using diabetic patients) | Higher severity and extension of coronary atherosclerosis were reported among opium-using diabetics than among age, sex, and smoking-matched non-opium-using diabetics. |
| Rezvani et al, 2011 | Cross-sectional | Addiction | N = 558 (161 opium addicts and 397 nonusers) | No association was found between opium consumption and ischemic heart disease. |
| Hosseini, 2012 | Cross-sectional | Opium consumer | N = 5442 (2874 opium users and 2568 nonusers) | Opium was an independent risk factor for CAD (OR = 1.31, 95% CI = 1.01 to 1.69; P = 0.042). |
| Khademi et al, 2012 | Cohort | Use of opium at least once a week for ≥ 6 mon | N = 1049 (566 isolated CABG patients was performed by Najafi and colleagues, who reported that opium consumption conferred no cardioprotective effects on addicted patients who underwent the operation. Nevertheless, they could not ignore the concurrent impact of cigarette smoking as a confounding variable. Najafi et al also carried out a study on 268 patients with a confirmed diagnosis of CAD who had undergone isolated CABG. Of the 268 patients, only 38 were addicted at the time of the surgery. However, the authors found no significant vessel involvement in any of the groups, but the mean EuroSCORE was higher in the opium addicts than that in the nonaddicts. Given the controversy surrounding the post-intervention continuation of opium consumption, in a retrospective study on 1545 patients with percutaneous coronary interventions history, Sharafi and colleagues evaluated the association between preprocedural opium consumption and major cardio-cerebrovascular events (MACCE). They found no significant correlation with MACCE between opium users and nonusers after percutaneous coronary interventions (11 [3.1%] vs 53 [4.4%]; P = 0.286, respectively). The unadjusted hazard of 1 year's MACCE in the opium users and nonusers was 0.704 (95% CI = 0.367 to 1.347; P = 0.289). |
Stroke
Hamzeh-Moghadam et al conducted a cross-sectional study on 97 patients with ischemic stroke (38 addicts). They observed that one-third of the patients with ischemic stroke were addicted to opium and that the rate was higher than that in the general population. In another case-control study, 672 patients with ischemic stroke were compared with 293 controls with no stroke or CAD history. In that study, Ebrahim and colleagues found that opium addiction was independently associated with ischemic stroke (OR = 2.36, 95% CI = 1.16 to 4.85; P = 0.018). More studies on the association between opium consumption and stroke are needed to clarify this relationship.

Peripheral Arterial Disease
Most studies indicate an association between ASCVD and opium consumption. There are limited studies evaluating the effects of opium on peripheral vascular disease. In a study by Shirani and colleagues, opium was assessed as a risk factor for significant carotid stenosis (≥ 70% of the luminal diameter) in 939 patients with CABG. Although the authors did not detect any difference in the prevalence of significant carotid artery stenosis in opium-addicted versus nonaddicted patients, it should be noted that the opium-addicted patients had lower prevalence rates of hypertension (88.6% vs 11.4%) and diabetes (17% vs 11.4%) and a higher prevalence rate of smoking (27.1% vs 65.5%) than the nonaddicts. However, Shirani et al did not adjust for confounding variables, and their findings should be interpreted cautiously. In another study, Jafarian et al evaluated factors affecting graft patency in 85 patients who had undergone infrainguinal revascularization. They demonstrated that the patency rate was significantly lower in patients with opium use (32%) than nonusers (67%) (P = 0.030). It seems that more well-designed studies should be performed in the future to elucidate the effects of opium on peripheral vascular disease.

Association between Opium Consumption and ASCVD in Cohort Studies
The best corroborating evidence for a potential hazardous role of opium use in ASCVD derived from the Golestan...
Cohort Study. The Golestan Cohort Study enrolled 50,045 individuals between 40 and 75 years of age from January 2004 to June 2008 from the Golestan province, located in northern Iran. After a follow-up median of 4.7 years, the adjusted hazard ratio (HR) was 1.86 (95% CI = 1.68 to 2.06) for all-cause mortality associated with the opium consumption. The study also revealed that opium consumers were at 90% increased risk of mortality from ischemic heart disease (adjusted HR = 1.90; 95% CI = 1.57 to 2.29). Moreover, after omitting the subjects who had started opium use after receiving a diagnosis of a major illness (e.g. ischemic heart disease, cerebrovascular events, diabetes mellitus, and hypertension), the researchers discovered a dose-response association between the duration of opium consumption and ASCVD as well as all-cause mortality. In a very recent publication of the Golestan Cohort Study, Nalini et al investigated the effects of long-term opiate use (crude opium or shireh [a derivative of opium made by boiling and filtering the opium, which has higher concentrations of morphine]) on cardiovascular mortality. They observed a significantly increased risk of mortality in opium users by comparison with nonusers (adjusted HR = 1.63; 95% CI = 1.49 to 1.79). We think that there is a strong correlation between opium use and ASCVD based on the Golestan Cohort Study.

**Association between Opium Consumption and Cancer**

A popular belief among laypeople and also some physicians is that the use of opium can improve the survival of patients with malignancy. This belief might be due to the analgesic properties of opium that relieves pain in these patients. During the past few years, many studies have demonstrated a positive connection between opium consumption and the development of various types of cancers. More recent studies have explored the effects of opium consumption on cell proliferation and metastasis. In the next section, we are going to review the evidence on the association between opium consumption and cancer and the biological basis for such an association.

**Laryngeal Cancer**

A case-control study by Mousavi et al on 98 patients with laryngeal cancer and 312 age- and gender-matched controls showed the possible association between opium consumption and laryngeal cancer. By adjusting for potential confounders, they demonstrated that use of opium was strongly associated with laryngeal cancer (OR = 10.74; 95% CI = 5.76 to 20.02; P < 0.002). Rahmati et al performed an analysis on data from the Golestan Cohort Study to investigate the relationship between opium consumption and mortality from respiratory malignancies. The results demonstrated that after adjustment for age, sex, residential place, education level, marital status, alcohol use, and the cumulative use of any type of tobacco, opium consumption was associated with an increased risk of laryngeal cancer, very close to significance, with lower bounds of CIs being 0.99. Bakhshaee et al evaluated the association between opium addiction and the risk of laryngeal carcinoma and found that the crude OR for laryngeal cancer in opium users was 9.09 (95% CI = 3.21 to 25.64; P = 0.000) relative to nonusers. Additionally, after adjustment for opium consumption with cigarette smoking, the OR for laryngeal cancer in opium users was 6.06 (95% CI = 1.10 to 33.23; P = 0.05). Laryngeal cancer was also detected in younger patients with opium dependency (54.54 ± 10.93; P = 0.02). More recently, Sheikh et al performed an analysis on data from the Golestan Cohort Study to evaluate opium use and the subsequent incidence of cancer. They reported that the use of opium was associated with an increased risk of developing laryngeal cancer (HR = 2.53, 95% CI = 1.21 to 5.30; P < 0.05). Table 3 demonstrates all studies performed on this topic and a summary of other studies on the association between opium consumption and cancer.

**Lung Cancer**

Lung cancer is well-known to be the most prevalent malignancy and the leading cause of mortality in the world. The results of a study by Rahmati et al on data from the Golestan Cohort Study showed that opium consumption was associated with an increased rate of lung cancer mortality (OR = 1.96; 95% CI = 1.18 to 3.25). The long-term use of opium also showed an increased rate of death due to respiratory malignancies (HR = 3.01; 95% CI = 1.55 to 5.81). In another analysis based on the Golestan Cohort Study, Sheikh et al investigated 1833 participants diagnosed with cancer during a median follow-up of 10 years and reported that opium use was associated with increased incidence of lung cancer (HR = 2.21, 95% CI = 1.44 to 3.39; P < 0.05).

**Esophageal Cancer**

Several reports have indicated a positive association between opium consumption and esophageal cancer with a dominant type of squamous cell carcinoma (ESCC). Ghadirian et al performed a case-control study on 82 patients to evaluate the association between the presence of morphine metabolites and esophageal cancer. They found that individuals with more than 1 µg/mL of morphine metabolites in their urine had a higher rate of esophageal cancer. Bakhshaie et al also performed a case-control study to evaluate the association between the risk of esophageal carcinoma and opium addiction. They demonstrated that the crude OR for esophageal cancer was 1.44 (95% CI = 0.57 to 3.62; P = 0.43) relative to nonusers. Other studies conducted on the population in the northern Iranian province of Golestan are known for a high incidence of esophageal cancer. In their case-control study, Nasrollahzadeh et al observed that 30% of patients with ESCC and 18% of controls were opium users. More interestingly, the authors observed an even stronger association between using shireh and ESCC than between
Opium consumption was significantly related to oral cavity cancer (OR = 4.0; 95% CI: 1.2 to 13.6).

Opium consumption was a factor for laryngeal cancer with a crude OR of 21.55 (95% CI: 10.54 to 44; P < 0.001). The adjusted odds ratio showed that opium was strongly associated with laryngeal cancer (OR = 10.74; 95% CI: 5.76 to 20.02; P < 0.0021).

Opium consumption was almost significantly associated with an increased risk of gastric cancer (95% CI: 0.99).

The use of opium was associated with an increased risk of laryngeal cancer (OR = 1.73; 95% CI: 0.99 to 3.03).

Opium consumption was associated with an increased risk of developing laryngeal cancer (HR = 2.53, 95% CI: 1.21 to 5.30; P < 0.05).

Opium consumption was associated with an increased risk of lung cancer (OR = 1.73; 95% CI: 1.09 to 2.40; P < 0.05).

Opium consumption was associated with an increased risk of developing lung cancer (HR = 2.21, 95% CI: 1.44 to 3.39; P < 0.05).

Individuals with more than 1 µg/mL of morphine metabolites in their urine had a higher rate of esophageal cancer.

The crude OR for laryngeal cancer in opium users was 9.09 (95% CI: 3.21 to 25.64; P = 0.000) compared to nonusers. After adjustments for opium with cigarette smoking, the OR for laryngeal cancer in opium users was 6.06 (95% CI: 1.10 to 33.21; P = 0.05). Laryngeal cancer was also discovered in younger patients with opium dependency (54.54 ± 10.93; P = 0.02).

The use of opium was associated with an increased risk of developing laryngeal cancer (HR = 2.53, 95% CI: 1.21 to 5.30; P < 0.05).

Opium use increased the risk of all gastric cancers (HR = 3.2; 95% CI: 1.4 to 7.7).

Opium use increased the risk of gastric cancer (95% CI: 1.2 to 13.6).

Opium consumption was almost significantly associated with an increased risk of laryngeal cancer (95% CI: 0.99).

After adjustments for potential confounders and exclusion of those who started opium use after major chronic illnesses, the use of opium was associated with a 69% increase in the risk of ESCC-related mortality (HR = 1.69, 95% CI: 1.11 to 2.56; P = 0.035).

The use of opium was associated with an increased risk of developing laryngeal cancer (HR = 2.21, 95% CI: 1.44 to 3.39; P < 0.05).

Opium increased the risk of all types of adenocarcinoma (OR = 3.1; 95% CI: 1.9 to 5.2). Opium consumption after a diagnosis of gastric cancer showed a significant increase in all types of gastric cancer (OR = 2.9; 95% CI: 1.7 to 4.8). Patients with the highest cumulative opium consumption demonstrated the poten relationship (OR = 4.5, 95% CI: 2.3 to 8.5).

Opium use increased the risk of all gastric cancers (HR = 3.2; 95% CI: 1.4 to 7.7).

The use of opium was associated with an increased risk of developing gastric cancer (HR = 1.36, 95% CI: 1.03 to 1.79; P < 0.05).

Sharing Impact of Opium on ASCVD and Cancer

| Study Reference | Type of Study | Study Population | Measured Outcome | Result |
|-----------------|---------------|------------------|-----------------|--------|
| Razmapi et al., 2014 | Case-control | 160 individuals (80 patients with oral cavity cancer) | Cancer incidence | Opium consumption was significantly related to oral cavity cancer (OR = 4.0; 95% CI: 1.2 to 13.6). |
| Mousavi et al., 2003 | Case-control | N = 410 (98 patients with laryngeal cancer and 312 cancer-free subjects) | Cancer prevalence | Opium consumption was a factor for laryngeal cancer with a crude OR of 21.55 (95% CI: 10.54 to 44; P < 0.001). The adjusted odds ratio showed that opium was strongly associated with laryngeal cancer (OR = 10.74; 95% CI: 5.76 to 20.02; P < 0.0021). |
| Rahmati et al., 2017 | Cohort | N = 50045 (8487 opium users and 43 mortality cases due to respiratory malignancies) | Cancer mortality | Opium consumption was almost significantly associated with an increased risk of gastric cancer (95% CI: 0.99). |
| Bakhshaei et al., 2017 | Case-control | N = 181 (58 cases with laryngeal cancer and 98 cases with esophageal cancer) | Cancer prevalence | The use of opium was associated with an increased risk of developing laryngeal cancer (HR = 2.53, 95% CI: 1.21 to 5.30; P < 0.05). |
| Sheikh et al., 2020 | Cohort | N = 50045 (8487 opium users and 1833 cases with cancer) | Cancer incidence | Opium consumption was almost significantly associated with an increased risk of laryngeal cancer (OR = 1.73; 95% CI: 0.99 to 3.03). |
| Rahmati et al., 2017 | Cohort | N = 50045 (8487 opium users and 43 mortality cases due to respiratory malignancies) | Cancer mortality | Opium consumption was associated with an increased risk of developing laryngeal cancer (HR = 2.21, 95% CI: 1.44 to 3.39; P < 0.05). |
| Sheikh et al., 2020 | Cohort | N = 50045 (8487 opium users and 1833 cases with cancer) | Cancer incidence | Opium consumption was associated with an increased risk of developing lung cancer (HR = 2.21, 95% CI: 1.44 to 3.39; P < 0.05). |
| Gahidian et al., 1985 | Case-control | N = 41 cases and 41 controls | Cancer prevalence | Individuals with more than 1 µg/mL of morphine metabolites in their urine had a higher rate of esophageal cancer. |
| Nasrollahzadeh et al., 2008 | Case-control | N = 871 (303 cases with ESCC and 571 cancer-free cases) | Cancer prevalence | Consuming shireh had a stronger association with ESCC than consuming usual opium (OR = 3.41; 95% CI: 1.35 to 8.60; and OR = 1.62; 95% CI: 1.09-2 to 40, respectively). Opium use and ESCC had a dose-response relationship. |
| Malekzadeh et al., 2013 | Cohort | N = 50045 (8487 opium users and 134 cases of GI mortality due to ESCC) | Cancer mortality | After adjustments for potential confounders and exclusion of those who started opium use after major chronic illnesses, the use of opium was associated with a 69% increase in the risk of ESCC-related mortality (HR = 1.69, 95% CI: 1.11 to 2.56; P = 0.035). |
| Bakhshaei et al., 2017 | Case-control | N = 181 (58 cases with laryngeal cancer and 98 cases with esophageal cancer) | Cancer prevalence | The use of opium was associated with an increased risk of developing laryngeal cancer (HR = 2.53, 95% CI: 1.21 to 5.30; P < 0.05). |
| Sheikh et al., 2019 | Cohort | N = 50045 (8487 opium users) | Cancer incidence | After adjustments for potential confounders such as age, gender, residence districts, ethnicity, and quartiles of the socioeconomic status, the results showed that smoking opium was associated with an increased risk of ESCC (HR = 1.85, 95% CI: 1.18 to 2.90; P = 0.009). |
| Sheikh et al., 2020 | Cohort | N = 50045 (8487 opium users and 1833 cases with cancer) | Cancer incidence | The use of opium was associated with an increased risk of developing esophageal cancer (HR = 1.38, 95% CI: 1.06 to 1.80; P < 0.05). |
| Malekzadeh et al., 2013 | Cohort | N = 50045 (8487 opium users and 125 cases with GI mortality due to gastric cancer) | Cancer mortality | After adjustments for possible confounding variables and exclusion of those who started opium use after major chronic illnesses, the use of opium was associated with a 22% increase in the risk of gastric-related mortality (HR = 1.22, 95% CI: 0.79 to 1.89). |
| Shakeri et al., 2013 | Case-control | N = 922 (309 cases of gastric adenocarcinoma and 613 matched controls) | Cancer prevalence | Opium increased the risk of all types of adenocarcinoma (OR = 3.1; 95% CI: 1.9 to 5.2). Opium consumption after a diagnosis of gastric cancer showed a significant increase in all types of gastric cancer (OR = 2.9; 95% CI: 1.7 to 4.8). Patients with the highest cumulative opium consumption demonstrated the potent relationship (OR = 4.5, 95% CI: 2.3 to 8.5). |
| Sadjadi et al., 2014 | Cohort | N = 928 Helicobacter-positive patients | Cancer incidence | Opium use increased the risk of all gastric cancers (HR = 3.2; 95% CI: 1.4 to 7.7). |
| Sheikh et al., 2020 | Cohort | N = 50 045 (8487 opium users and 1833 cases with cancer) | Cancer incidence | The use of opium was associated with an increased risk of developing gastric cancer (HR = 1.36, 95% CI: 1.03 to 1.79; P = 0.05). |
usual opium and ESCC (OR = 3.41; 95% CI = 1.35 to 8.60 and OR = 1.62; 95% CI = 1.09 to 2.40, respectively). These results were further supported and expanded by the Golestan Cohort Study, which demonstrated that after adjustment for potential confounding variables and the exclusion of those who started opium consumption in the wake of a major chronic disease (including CAD, stroke, diabetes mellitus, and hypertension), the use of opium was related with a 69% increased risk of ESCC-related mortality (HR = 1.69; 95% CI = 1.11 to 2.56) in a dose-dependent manner. Another report of the Golestan Cohort Study demonstrated that, after adjustments for potential variables including age, gender, residence districts, ethnicity, and quartiles of the socioeconomic status, opium use was associated with a dose-response increased risk of ESCC (HR = 1.85; 95% CI = 1.18 to 2.90; P = 0.009). A more recent analysis of their data also showed that opium use was associated with a
risk of developing esophageal cancer (HR = 1.38, 95% CI = 1.06 to 1.80; P < 0.05), dose-dependently. Studies are summarized in Table 3.

**Gastric Adenocarcinomas**
Different investigations have shown a strong relationship between opium use and gastrointestinal tract carcinoma, which counts as the second cause of cancer-related mortality worldwide and the most common cause of cancer in Iran. For instance, an analysis of the Golestan Cohort Study by Malekzadeh et al showed that the use of opium was associated with a 22% increase in the risk of gastric-related mortality (HR = 1.22; 95% CI = 0.79 to 1.89). In another case-control study in the Golestan Province of Iran, Shakeri et al evaluated 922 patients (309 cases of gastric adenocarcinoma) and demonstrated that opium consumption after the diagnosis of gastric cancer exhibited a significant rise in all types of gastric cancer (OR = 2.9; 95% CI = 1.7 to 4.8). Moreover, those with the highest cumulative opium consumption showed the strongest relationship (OR = 4.5; 95% CI = 2.3 to 8.5). Sadjadi et al performed a cohort study on 928 Helicobacter-positive patients and observed that opium use was significantly associated with baseline antral and body intestinal metaplasia (OR = 3.2, 95% CI = 1.2 to 9.1; P = 0.022 and OR = 7.3, 95% CI = 2.5 to 21.5; P = 0.001, respectively). Opium use increased the prevalence of all gastric cancers (HR = 3.2; 95% CI = 1.4 to 7.7). Sheikh et al performed another analysis from the Golestan Cohort Study to evaluate the association between opium consumption and developing gastric carcinoma. They found that the use of opium was associated with an increased risk of the development of gastric cancer (HR = 1.36, 95% CI = 1.03 to 1.79; P < 0.05).

**Pancreatic Cancer**
Shakeri and colleagues observed that after adjustment for potential confounding variables including age and the duration and cumulative use of opium, a relationship was observed between opium consumption and the risk of pancreatic cancer (OR = 1.91; 95% CI = 1.06 to 3.43) without a dose-response relationship. In an analysis of the Golestan Cohort Study, Moosavii and colleagues identified a greater effect of opium ingestion (HR = 2.38, 95% CI = 1.00 to 5.69; P = 0.05) in comparison to its inhalation (HR = 1.88; 95% CI = 0.91 to 3.89) on the incidence of pancreatic cancer. After adjustment for the cumulative dose of cigarette smoking, the authors also detected that high cumulative use of opium was significantly associated with the risk of pancreatic cancer (HR = 3.56, 95% CI = 1.49 to 8.50; P = 0.090).

**Colorectal Carcinomas**
A few studies have explored the association between opium consumption and colorectal carcinomas (CRCs), including colon, rectum, and anus cancers. Naghizadeh-Tahami et al conducted a case-control study on 175 patients with CRC and 350 healthy individuals to observe any possible association between opium consumption and the incidence of CRCs. They demonstrated that opium and its derivatives were associated with an increased risk of all CRCs (OR = 4.5; 95% CI = 2.4 to 8.7) and colon cancers (OR = 5.7; 95% CI = 2.7 to 11.9). They observed strong relationships between the daily dose and the duration of opium consumption and CRCs and colon cancers. Dianatnasab et al performed a prospective cohort study on 220 patients with CRCs to determine their mortality rate. They demonstrated that opium consumption was significantly associated with a higher risk of CRC-related mortality (HR = 2.49, 95% CI = 1.41 to 4.42; P < 0.001).

**Bladder Cancer**
Sadeghi et al were the first to perform a case-control study on 189 patients in Iran to demonstrate a correlation between opium addiction and bladder cancer. Afterwards, many investigators reported such an association between opium consumption and bladder cancer (Table 3). The dominant histological type was transitional-cell carcinoma in most of the studies. Akbari et al observed a significant relationship between opium consumption and the prevalence of bladder cancer after adjustment for potential confounding variables including nutritional factors and tobacco use (OR = 3.9; 95% CI = 1.3 to 12.0). Additionally, they observed a significant dose-response relationship between opium use and bladder cancer (OR = 4.9; 95% CI = 1.1 to 21.9). Opium has been demonstrated to have a deleterious effect on cell survival insofar as it increases the metastasis of cells in the urinary system. A systematic-review and meta-analysis was conducted by Afshari and colleagues to evaluate the association between opium consumption and the development of bladder cancer. The OR for the association between bladder cancer and opium use (without cigarette smoking) was 3.85 (95% CI = 3.05 to 4.87), which increased to 5.7 (95% CI = 1.9 to 16.3) when both opium use and cigarette smoking were examined. Another analysis of the Golestan Cohort Study demonstrated a significant association between opium consumption and bladder cancer (HR = 2.86, 95% CI = 1.47 to 5.55; P < 0.05).

**Other Types of Cancer**
Razmpa and colleagues evaluated the connection between opium use and oral cavity cancer in 160 individuals (80 patients with oral cavity cancer). They demonstrated that opium consumption was significantly related to oral cavity cancer (OR = 4.0; 95% CI = 1.2 to 13.6).

**The Shared Role of Opium in the Pathogenesis of ASCVD and Cancer**

**Inflammation**
It is well known that chronic low-grade inflammation has a pivotal role in the formation of atherosclerotic plaques and their progression. Atherosclerotic plaques contain many pro-inflammatory cytokines such as C-reactive protein...
(CRP), interleukin-1 (IL-1), tumor necrosis factor-α, and interferon-γ (INF-γ)\textsuperscript{77} that accelerate atherogenesis. This lipid-rich, inflamed microenvironment of plaques also contains reactive oxygen species (ROS) and oxidized low-density-lipoprotein cholesterol, causing increased inflammatory signaling, foam cell formation, and angiogenesis.

Rudolf Virchow in the 19th century claimed that there was a link between inflammation and cancer.\textsuperscript{78} He found that several solid cancers were triggered by chronic inflammatory state, inflamed environments, and interactions of mediators.\textsuperscript{1} Tumor growth depends on the activation of a wide range of pathways such as Janus-activated kinase, mitogen-activated protein kinase, and protein kinase B that can progress the carcinogenesis of affected cells and promote malignancy by the transcriptional activation of pro-inflammatory, pro-survival, and proteolytic programs via the signal transducer and activator of transcription, nuclear factor-κB, and hypoxia-inducible factor-1α.\textsuperscript{79-82} Furthermore, ROS and subsequent reactive nitrogen species can stimulate DNA destruction and resultant mutations in oncogenes and tumor suppressor genes could result in carcinogenesis.\textsuperscript{81,82}

In conclusion, inflammation and oxidative stress have an important part in the pathogenesis of both CVD and cancer. Recent studies have shown that chronic exposure to opium enhances the levels of pro-inflammatory mediators including CRP, IL-17, IL-6, INF-γ, IL-1 receptor antagonist, and C3 and C4 complement factors and decreases the levels of cytokines like transforming growth factor-β.\textsuperscript{83-85} Hence, chronic exposure to opium could initiate/accelerate atherogenesis and carcinogenesis by enhancing inflammation and oxidative stress.

**Plasminogen Activator Inhibitor-1**

Plasminogen activator inhibitor-1 (PAI-1) accounts as an inhibitor of fibrinolysis.\textsuperscript{86} There is accumulating evidence that PAI-1 is involved in atherogenesis; its activation promotes thrombus formation, stabilizes the fibrin matrix, and stimulates vascular smooth muscle cell proliferation and low-density lipoprotein uptake into the plaque.\textsuperscript{87,88} Additionally, it has been shown that levels of PAI-1 are increased in individuals with various types of cancer\textsuperscript{86,89-92} and predict worse prognoses.\textsuperscript{93-95} Recent studies have demonstrated that levels of PAI-1 are higher in opium addicts than nonusers. More interestingly, there is evidence that opioid receptors are present on various cancer cell types and the main alkaloids of opium-like morphine could upregulate the expression of the PAI-1 gene and, therefore, increase the progression of tumor cells.\textsuperscript{96} Hence, it could explain, at least in part, the increased risk of atherosclerosis and cancer in opium users.

**Adipokine (Adiponectin)**

Adiponectin is a unique adipokine which has beneficial metabolic properties including anti-inflammatory, anti-oxidant, anti- or pro-atherogenic, and insulin sensitizing effects. It is a potential prognostic biomarker and a therapeutic target for patients with CVD that have atherosclerosis, inflammation, and insulin resistance.\textsuperscript{97} Moreover, evidence proposes that adiponectin may have connection with the pathogenesis of several malignancies and their poor prognoses.\textsuperscript{98} Generally, serum adiponectin levels are reduced in various cancers, including breast,\textsuperscript{99} endometrial,\textsuperscript{100} CRC,\textsuperscript{101} hematologic,\textsuperscript{102} pancreatic,\textsuperscript{103} lung,\textsuperscript{104} prostate,\textsuperscript{106} esophageal,\textsuperscript{106} and gastric\textsuperscript{106} cancer. A recent investigation has shown that the adiponectin level is lower in opium consumers than in no consumers.\textsuperscript{107} The decreased levels of adiponectin could explain, at least in part, the increased risk of CVD occurrence and cancer in opium users.

**Homocysteine**

Hyperhomocysteinemia is known to be an independent risk factor for ASCVD.\textsuperscript{108-112} Homocysteine can cause vascular lesion, atherogenesis, thrombogenesis, hyperplasia, endothelial dysfunction, decreased nitric oxide and stimulating vascular smooth muscle cell proliferation.\textsuperscript{109,113} Recent studies have also proven that there is a close link between hyperhomocystinuria and cancer and it is a novel potential tumor biomarker.\textsuperscript{114} Moreover, several polymorphisms in the enzymes involved in the homocysteine detoxification pathways have close clinical ties to several cancer types, such as breast,\textsuperscript{115} CRC,\textsuperscript{116} acute lymphoblastic leukemia\textsuperscript{117} and prostate.\textsuperscript{118} Masoomi et al demonstrated that opium consumption was strongly accompanied by increased levels of homocysteine, which could explain the increased incidence of CVD and cancer in opium users.\textsuperscript{119}

**Fibrinogen**

Fibrinogen is an independent risk factor for ASCVD.\textsuperscript{120} Increased levels of fibrinogen are associated with the development of ASCVD through platelet aggregation, fibrin formation, atherosclerotic plaque evolution, and thrombus formation.\textsuperscript{121,123} In a few recent studies, convincing evidence has been provided to demonstrate that plasma fibrinogen is associated with tumor progression and poor prognoses in lung,\textsuperscript{124} breast,\textsuperscript{125} gastric,\textsuperscript{126} ovarian,\textsuperscript{127} oral and oropharyngeal,\textsuperscript{128} biliary tract,\textsuperscript{129,130} and penile cancer. Fibrinogen/fibrin seems to simplify the microvascular entrapment necessary for metastasis and to contribute to the formation of the connective tissue (stroma) of some forms of solid tumor.\textsuperscript{131,132} There is evidence that opium consumption is associated with increased levels of clotting factors such as fibrinogen, explaining partially the increased risk of cancer development and ASCVD in opium users.\textsuperscript{133,134}

**HbA1c**

HbA1c is a well-known marker of long-term glycemic control in patients with diabetes mellitus, and elevated HbA1c levels are correlated with an increased risk for future microvascular and macrovascular disease. A few
studies have shown HbA1c to be predictive of CAD in nondiabetics and to be correlated with the severity of CAD.\textsuperscript{135,136} Additionally, evidence also suggests that elevated HbA1c is related with an increased risk of developing certain types of cancer compared with nondiabetics, with the strongest associations seen with hepatic, pancreatic, endometrial, renal, breast, esophageal, colorectal, and bladder cancer.\textsuperscript{137} Recently, contrary to the traditional belief that opium consumption decreases blood glucose and insulin resistance, it has been found that HbA1c is higher in opium users than in nonusers.\textsuperscript{11,16,133} Hence, it could also justify the increased risk of ASCVD and cancer in opium users.

**Factor VII**

Factor VII (FVII) contributes to the initiation of the extrinsic pathway by binding to tissue factor. Coagulation cascade and platelet activation and subsequent acute coronary events is led by the formation of the FVII complex.\textsuperscript{138,139} Additionally, mounting evidence suggests that the tissue factor-FVII complex is involved in pathophysiological processes of cancer development, including angiogenesis, tumor migration and invasion, and cell survival.\textsuperscript{138,140,141} Asgary et al demonstrated that opium users had higher levels of FVII than nonusers, which could also explain the higher risk of ASCVD and cancer in opium users.\textsuperscript{133}

**Limitations of Studies on the Association Between Opium and ASCVD and Cancer**

As we reviewed in previous sections and summarized in tables, the majority of the studies evaluating the association between opium consumption and ASCVD and cancer have case-control or cross-sectional designs. Case-control studies are excellent for studying rare/non-prevalent diseases such as cancer; however, they carry some inherent limitations that call for attention when interpreting their results. Although case-control clinical studies have demonstrated the relationship between opium consumption CAD, stroke, and cancer, we cannot make a causative interpretation because the temporal relationship between opium consumption and ASCVD or cancer cannot be determined in these studies. Indeed, it is likely that some people with ASCVD, stroke, or cancer start consuming opium due to their symptoms/belief about the advantageous effects of opium use on ASCVD or cancer following the development of their disease. Thus, as we witness a higher prevalence of opium usage among patients with ASCVD or cancer than among normal controls, we cannot make a causal interpretation. Despite the high prevalence of opium consumption among Eastern people, opium carries a stigma for the individual and its reporting varies between patients and healthy individuals. It is expected that healthy individuals within the control group under-report their opium consumption that would result in the overestimation of the outcomes of opium consumption on the development of ASCVD or cancer.

Nonetheless, cohort studies can overcome the limitation of temporality and unbalanced reporting of exposure to opium. Fortunately, almost all of the aforementioned concerns have been regarded and minimized thanks to the results of the Golestan Cohort Study.

In conclusion, although ASCVD and cancer are seemingly different types of disease, they have multiple shared pathogenesis mechanisms and lifestyle-related risk factors like smoking, unhealthy diet, excessive alcohol consumption, and inadequate physical activity. We believe that opium consumption should be added to the current list of the lifestyle-related shared risk factors of ASCVD and cancer and special strategies should be developed and conducted for more comprehensive joint preventive programs that target both top-ranking killers in the world.

**Authors’ Contribution**

FM and NS generated the idea of a review article. FM and NY drafted the article. RM, KZ, AM, AVF, AI, MT, PR, KTA, and NS edited the manuscript independently and made critical scientific revisions.

**Conflict of Interest Disclosures**

The authors declare that they have no conflicts of interest.

**Ethical Statement**

Not applicable.

**Funding Sources**

The authors received no financial support for the research, authorship, and/or publication of this article.

**References**

1. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104-14. doi: 10.1161/circulationaha.115.020406.
2. World Health Organization. Global Status Report on Noncommunicable Diseases 2014. Available from: https://apps.who.int/iris/handle/10665/148114.
3. Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019;115(5):844-53. doi: 10.1093/cvr/cvz035.
4. UN. General Assembly. Political Declaration of the High-Level Meeting of the General Assembly on the Prevention and Control of Non-Communicable Diseases. New York: United Nations; 2011.
5. World Health Organization. The World Health Report: 2002: Reducing Risks, Promoting Healthy Life. Available from: https://www.who.int/publications/i/item/9241562072.
6. Zand S, Shafiee A, Boroumand M, Jalali A, Nozari Y. Serum uric acid is not an independent risk factor for premature coronary artery disease. Cardiorenal Med. 2013;3(4):246-53. doi: 10.1159/000355484.
7. Lee DK, Nathan Grantham R, Trachte AL, Mannion JD, Wilson CL. Activation of the canonical Wnt/beta-catenin pathway enhances monocyte adhesion to endothelial cells. Biochem Biophys Res Commun. 2006;347(1):109-16. doi: 10.1016/j.bbr.2006.06.082.
8. Masoudkabir F, Sarafzadegan N, Gotay C, Iqzanszewski A, Krahm AD, Davis MK, et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343-51. doi: 10.1016/j.atherosclerosis.2017.06.001.
Masoudkabir et al.

9. United Nations Office on Drugs and Crime. World Drug Report 2020. Available from: http://vngoc.org/wp-content/uploads/2020/07/wdr2020_Presentation-CSO_EN_27072020-rev.pdf.

10. Wamakulaurieru S, Cronin-Fenton D, Jinot J, Kamangar F, Malekzadeh R, Dir NA, et al. Carcinogenicity of opium consumption. Lancet Oncol. 2020;21(11):1407-8. doi:10.1016/s1470-2045(20)30611-2.

11. Masoudkabir F, Sarrafzadegan N, Eisenberg MJ. Effects of opium consumption on cardiometabolic diseases. Nat Rev Cardiol. 2013;10(12):733-40. doi:10.1038/nrcardio.2013.159.

12. Karbakhsh M, Salehian Zandi N. Acute opiate overdose in Tehran: the forgotten role of opium. Addict Behav. 2007;32(9):1835-42. doi:10.1016/j.addbeh.2006.12.014.

13. Kulsudjarit K. Drug problem in southeast and southwest Asia. Ann N Y Acad Sci. 2004;1025:446-57. doi:10.1196/annals.1316.055.

14. Sadri-Balghi SM, Rafiee M, Bahadorzadeh L, Namayeh SM, Soltani MH, Andishmand MM. Is opium addiction a risk factor for acute myocardial infarction? Acta Med Iran. 2005;43(3):218-22.

15. Farahani MA, Mohammadi E, Ahmadi F, Maleki M, Hajizadeh E. Cultural barriers in the education of cardiovascular disease patients in Iran. Int Nurs Rev. 2008;55(3):360-6. doi:10.1111/j.1466-7657.2008.00635.x.

16. Asadikaram G, Reisi M, Alizadeh Kaseb A, Khaksari M, Mohammadi A, Mahmoudi M. Effects of opium addiction on some serum factors in addicts with non-insulin-dependent diabetes mellitus. Addict Biol. 2004;9(1):53-8. doi:10.1080/1355621041000167495.

17. Mohammadi A, Darabi M, Nasri M, Saadet-Jahromi MJ, Malek-Pour-Afsar R, Sheibani H. Effect of opium addiction on lipid profile and atherosclerosis formation in hypercholesterolemic rabbits. Exp Toxicol Pathol. 2009;61(1):145-9. doi:10.1016/j.etp.2008.08.001.

18. Asadikaram G, Vakili S, Akbari H, Kheirmand-Parizi M, Sadeghi E, Asibamna M, et al. Effects of opium addiction on some biochemical factors in diabetic rats. Addict Health. 2018;10(2):123-30. doi:10.22122/ahj.v10i2.531.

19. Najafipour H, Joukar S. Combination of opium smoking and hypercholesterolemia augments susceptibility for lethal cardiac arrhythmia and atherogenesis in rabbit. Environ Toxicol Pharmacol. 2012;34(2):154-9. doi:10.1016/j.etp.2012.02.008.

20. Najafipour H, Joukar S, Malekpour-Afsar R, Mirzaeipour F, Nasri HR. Passive opium smoking does not have beneficial effect on plasma lipids and cardiovascular indices in hypercholesterolemic rabbits with ischemic and non-ischemic hearts. J Ethnopharmacol. 2010;127(2):257-63. doi:10.1016/j.jep.2009.11.011.

21. Joukar S, Najafipour H, Malekpour-Afsar R, Mirzaeipour F, Nasri HR. The effect of passive opium smoking on cardiovascular indices of rabbits with normal and ischemic hearts. Open Cardiovasc Med J. 2010;4:1-6. doi:10.2174/1874192901004010001.

22. Sadeghian S, Davish S, Davoodi G, Salarifar M, Mahmoodian M, Fallah N, et al. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2007;14(3):715-7. doi:10.1097/HCR.0b013e328045c4e9.

23. Sadeghian S, Graili P, Salarifar M, Katimi AA, Davish S, Abbasi SH. Opium consumption in men and diabetes mellitus in women are the most important risk factors of premature coronary artery disease in Iran. Int J Cardiol. 2010;141(1):116-8. doi:10.1016/j.ijcard.2008.11.063.

24. Hosseini SA, Abdollahi AA, Behnampour N, Salehi A. The relationship between coronary risk factors and coronary artery involvement based on angiography findings. Koomesh. 2012;14(1):7-12. [Persian].

25. Rahimi Darabad B, Vatandoust J, Pourmousavi Khoshknab MM, Hajjamahdi Poorrasansanjani M. Survey of the effect of opioid abuse on the extent of coronary artery diseases. Glob J Health Sci. 2014;6(7): Spec No.:83-91. doi:10.5359/gjhs.v6n7p83.

26. Pournelle Nafisadeh A, Pour Amiri F, Sheikh Fathollahi M, Hassanabadi G, Ahmadi Z, Sayadi AR. Opium addiction as an independent risk factor for coronary microvascular dysfunction: a case-control study of 250 consecutive patients with slow-flow angiina. Int J Cardiol. 2016;219:301-7. doi:10.1016/j.ijcard.2016.06.034.

27. Masoumi M, Ramezani MA, Karimzadeh H. The relationship of opium addiction with coronary artery disease. Int J Prev Med. 2010;1(3):182-6.

28. Masoumi M, Shahesmaeili A, Mirzaezadeh A, Tavakoli M, Zia Ali A. Opium addiction and severity of coronary artery disease: a case-control study. J Res Med Sci. 2010;15(1):27-32.

29. Hosseini SK, Masoudkabir F, Vasheghani-Farahani A, Alipour-Parsa S, Sheikh Fathollahi M, Rahimi-Fouroushani A, et al. Opium consumption and coronary atherosclerosis in diabetic patients: a propensity score-matched study. Planta Med. 2011;77(17):1870-5. doi:10.1055/s-0031-1280017.

30. Khademi H, Malekzadeh R, Poursams A, Jafari E, Salahi R, Semnani S, et al. Opium use and mortality in Golesan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ. 2012;344:e2502. doi:10.1136/bmj.e2502.

31. Rezvani MR, Ghandehari K. Is opium addiction a risk factor for ischemic heart disease and ischemic stroke? J Res Med Sci. 2012;17(10):958-61.

32. Nakhaei S, Amirabadizadeh A, Qorbani M, Lamarine RJ, Mehrpour O. Opium use and cardiovascular diseases: a systematic review and meta-analysis. Crit Rev Toxicol. 2020;50(3):201-12. doi:10.1080/10408444.2020.1740972.

33. Roohefza H, Talei M, Sadeghi M, Haghani P, Shokouh P, Sarrafzadegan N. Opium decreases the age at myocardial infarction and sudden cardiac death: a long- and short-term outcome evaluation. Arch Iran Med. 2013;16(3):154-60.

34. Harati H, Shamsi A, Firouzoukh Moghadam M, Seyed Zadeh FS, Ghazi A. The mortality rate of myocardial infarction patients with and without opium dependen. Int J High Risk Behav Addict. 2015;4(3):e22576. doi:10.5812/ijhrba.22576.

35. Masoomi M, Zare J, Nasri H, Mirzaezadeh A, Sheikhwatan M. Abrupt opium discontinuation has no significant triggering effect on acute myocardial infarction. J Cardiovasc Med (Hagerstown). 2011;12(4):234-8. doi:10.1097/JCM.0b013e328343d5b7.

36. Dehghani F, Masoomi M, Haghdoost AA. Relation of opium addiction with the severity and extension of myocardial infarction and its related mortality. Addict Health. 2013;5(1-2):35-42.

37. Azimzade-Sarwar B, Yousefzade G, Narooey S. A case-control study of effect of opium addiction on myocardial infarction. Am J Appl Sci. 2005;2(7):1134-5.

38. Davoodi G, Sadeghian S, Akhdondzadeh S, Davish S, Alidostoo M, Amirzadegan A. Comparison of specifications, short term outcome and prognosis of acute myocardial infarction in opium dependent patients and nondependents. J Tehran Heart Cent. 2006;11(1):48-53.

39. Javadi HR, Allami A, Mohammadi N, Alauddin R. Opium dependency and in-hospital outcome of acute myocardial infarction. Med J Islam Repub Iran. 2014;28:122.

40. Mirzaeipour F, Dadras M, Forood A, Najafipour H, Shokouhi M. The effect of opium addiction on arrhythmia following acute myocardial infarction. Acta Med Iran. 2012;50(10):670-5.

41. Khosooosi Niaki MR, Hamid M, Farshidi F, Mohammadpour M, Salehi Omran MT. Evaluation of the role of opium addiction in acute myocardial infarction as a risk factor. Caspian J Intern Med. 2013;4(1):585-9.
42. Najafi M, Jahangiry L, Mortazavi SH, Jalali A, Karimi A, Bozorgi A. Outcomes and long-term survival of coronary artery surgery: the controversial role of opium as risk marker. World J Cardiol. 2016;8(11):676-83. doi: 10.4330/wjc.v8.i11.676.

43. Najafi M, Sheikhtwatan M. Does analgesic effect of opium hamper the adverse effects of severe coronary artery disease on quality of life in addicted patients? Anesth Pain Med. 2012;22(1):22-7. doi: 10.5812/apm.5139.

44. Shariati A, Pour Hosseini HR, Jalali A, Salari Far E, Shoijanasab M, et al. Opium consumption and mid-term outcome of percutaneous coronary intervention in men. J Tehran Heart Cent. 2014;9(3):115-9.

45. Hamzei-Moghaddam A, Shafa MA, Khajani N, Farahat R. Frequency of opium addiction in patients with ischemic stroke and comparing their cerebrovascular doppler ultrasound changes to non-addicts. Addict Health. 2013;5(3-4):95-101.

46. Ebrahimi H, Haghigho Jannamard S, Asgary S, Dehghani L, Amiri M, Saadatnia M. Opium addiction and ischemic stroke in Isfahan, Iran: a case-control study. Eur Neurol. 2018;79(1-2):82-5. doi: 10.1159/000485098.

47. Shirani M, Alkhatib M, Soleymanzadeh M, Esfandebod M. Can opium abuse be a risk factor for carotid stenosis in patients who are candidates for coronary artery bypass grafting? Cardiol J. 2010;17(3):254-8.

48. Jafarian A, Elyasnia F, Keramati MR, Ahmadi F, Parsaei R. Surgical infrainguinal revascularization for peripheral arterial disease: factors affecting patency rate. Med J Islam Repub Iran. 2015;29:278.

49. Pourshams A, Khadem H, Malekshah AF, Isfami F, Noureai M, Sadjadi AR, et al. Cohort Profile: The Golestan Cohort Study—a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010;39(1):52-9. doi: 10.1093/ije/dyp161.

50. Nalini M, Shakeri R, Pourshams H, Pourshams A, Etemadi A, Isfami F. Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study. Eur J Prev Cardiol. 2021;28(1):98-106. doi: 10.1177/2047487320973427.

51. Ahmadi Mosavi MR, Damghani MA, Haghdoust AA, Khamesipour A. Opium and risk of laryngeal cancer. Laryngoscope. 2003;113(11):1939-43. doi: 10.1097/00005537-200311000-00016.

52. Rahmati A, Shakeri R, Khadem H, Pourshci H, Pourshams A, et al. Mortality from respiratory diseases associated with opium use: a population-based cohort study. Thorax. 2017;72(11):1028-34. doi: 10.1136/thoraxjnl-2015-208251.

53. Bakhsheh M, Raziee HR, Afshari R, Amali A, Roozloosh M, Lotfizadeh A. Opium addiction and risk of laryngeal and esophageal carcinoma. Iran J Otolarhinolaryngol. 2017;29(90):22-7. doi: 10.5812/apmr.5139.

54. Sheikh M, Shakeri R, Pourshci H, Pourshams A, Etemadi A, Isfami F, et al. Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study. Lancet Glob Health. 2020;8(5):e649-60. doi: 10.1016/s2214-109x(20)30059-0.

55. Ghdairian P, Stein GF, Gorodetzky C, Robbernfd MB, Mahon GA, Bartsch H, et al. Oesophageal cancer studies in the Caspian littoral of Iran: some residual results, including analysis. Urol Oncol. 2010;28(6):610-6. doi: 10.1016/j.urolonc.2008.10.016.

56. Shakeri R, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Soloudeh M, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455-61. doi: 10.1002/ijc.28018.

57. Shakeri R, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Soloudeh M, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455-61. doi: 10.1002/ijc.28018.

58. Najafi M, Niazi SR, Poustchi H, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Soloudeh M, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455-61. doi: 10.1002/ijc.28018.

59. Najafi M, Niazi SR, Poustchi H, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Soloudeh M, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455-61. doi: 10.1002/ijc.28018.

60. Najafi M, Niazi SR, Poustchi H, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Soloudeh M, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455-61. doi: 10.1002/ijc.28018.

61. Najafi M, Niazi SR, Poustchi H, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Soloudeh M, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455-61. doi: 10.1002/ijc.28018.
vascular perturbations: mechanistic links between obesity, inflammation, and cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-81. doi: 10.1093/carcin/bgp127.

80. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4(4):221-33. doi: 10.1158/1541-7786.mcr-05-0261.

81. Kundu JK, Surti Y, Emerging avenues linking inflammation and cancer. Free Radic Biol Med. 2012;52(9):2013-37. doi: 10.1016/j.freeradbiomed.2012.02.035.

82. Wu Y, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett. 2014;345(2):164-73. doi: 10.1016/j.canlet.2013.08.014.

83. Lashkarizadeh MR, Hashashibi M, Shabani M, Dabiri S, Hadavi H, Manafi-Anari H. Impact of opioid addiction on levels of pro- and anti-inflammatory cytokines after surgery. Addict Health. 2016;8(1):9-15.

84. Ghazavi A, Solhi H, Moazzeni SM, Rafiei M, Mosayebi G. Cytokine profiles in long-term smokers of opium (Taryaki). J Addict Med. 2013;7(3):200-3. doi: 10.1097/ADM.0b013e1828baeae.

85. Nabati S, Asadikaram G, Kazemi Arababadi M, Shahabinejad G, Rezaeein M, Mahmoudi M, et al. The plasma levels of the cytokines in opium-addicts and the effects of opium on the cytokines secretion by their lymphocytes. Immunol Lett. 2013;152(1):42-6. doi: 10.1016/j.imlet.2013.04.003.

86. Forood A, Malekpour-Afsar R, Mahmoudi A. Serum level of plasminogen activator inhibitor type-1 in addicted patients with coronary artery disease. Addict Health. 2014;6(3-4):119-26.

87. Plopis VA. Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr Drug Targets. 2011;12(12):1782-9. doi: 10.2174/138945011797635803.

88. Liu CC, Prior J, Piwnica-Worms D, Bu G. LRPs overexpression defines a class of breast cancer subtypes and is a target for therapy. Proc Natl Acad Sci U S A. 2010;107(11):5136-41. doi: 10.1073/pnas.0912010107.

89. Fang H, Placencia VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst. 2010;102(19):1740-8. doi: 10.1093/jnci/djv080.

90. Nordr TK, Loehrman J, Bode C. Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis. Thromb Res. 2001;103 Suppl 1S:5-10. doi: 10.1016/s0049-3848(01)00292-4.

91. Iwaki T, Urao T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol. 2012;157(3):291-8. doi: 10.1111/j.1365-2411.2012.09747.x.

92. Hursting SD, Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol. 2012;32(8):1766-70. doi: 10.1161/atvbaha.111.241927.

93. Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4(8):923-8. doi: 10.1038/nm989-923.

94. Dufy MJ. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem Soc Trans. 2002;30(2):207-10.

95. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994;54(11):2900-7.

96. Gach K, Szmraj F, Ficjna J, Piestrzeniewicz M, Delbro DS, Janecka A. The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line. Chem Biol Drug Des. 2009;74(4):390-6. doi: 10.1111/j.1747-0285.2009.00875.x.

97. Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis.Curr Opin Lipidol. 2017;28(4):347-54. doi: 10.1097/mol.0000000000000431.

98. Katira A, Tan PH. Evolving role of adiponectin in cancer-controversies and update. Cancer Biol Med. 2016;13(1):101-19. doi: 10.28092/j.issn.2095-3941.2015.00092.

99. Mantzoros C, Petridou E, Desypris N, Chavelas C, Dalamaga A, Mulexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89(3):1102-7. doi: 10.1210/jc.2003-031804.

100. Zheng Q, Wu H, Cao J. Circulating adiponectin and risk of endometrial cancer. PLoS One. 2015;10(6):e0129824. doi: 10.1371/journal.pone.0129824.

101. Joshi RK, Kim WJ, Lee SA. Association between obesity-related adipokines and colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol. 2014;20(24):7941-9. doi: 10.3748/wjg.v20.i24.7941.

102. Aref S, Ibrahim L, Azmy E, Al Ashary R. Impact of serum adiponectin and leptin levels in acute leukemia. Hematol. 2013;18(4):198-203. doi: 10.11197/1607845412.y.00000059.

103. Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013;105(2):93-103. doi: 10.1093/jnci/djt474.

104. Arisan ED, Arisan S, Atis G, Palavan-Unsal N, Ergenekon E. Serum adipocytokine levels in prostate cancer patients. Urol Int. 2009;83(2):203-8. doi: 10.1159/000200801.

105. Vildoirim A, Bilici M, Cayir K, Yannaz V, Vildoirim S, Tekin SB. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol. 2009;39(2):92-6. doi: 10.1093/jjco/hyp143.

106. Ishikawa M, Kitayama J, Kazama S, Hiratani T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11(2):PI:1:466-72.

107. Shahouzehi B, Shokoohi M, Najafiour H. The effect of opioid addiction on serum adiponectin and leptin levels in male subjects: a case control study from Kerman Coronary Artery Disease Risk Factors Study (KERCADRS). EXCLI J. 2013;12:916-23.

108. Raina JK, Sharma M, Panjaliya RK, Bhagat M, Sharma R, Bakaya A, et al. Methyltetrahydrofolate reductase C677T and methionine synthase A2756G gene polymorphisms and associated risk of cardiovascular diseases: a study from Jammu region. Indian Heart J. 2016;68(3):421-30. doi: 10.1016/j.iji.2016.02.009.

109. Bennounar N, Allami A, Azeddoug H, Bendris A, Larauqi A, El Jaffali A, et al. Thermolabile methylenetetrahydrofolate reductase C677T polymorphism and homocysteine are risk factors for coronary artery disease in Moroccan population. J Biomed Biotechnol. 2007;2007(1):80687. doi: 10.1155/2007/80687.

110. Li YY. Methyltetrahydrofolate reductase C677T gene.
polymorphism and coronary artery disease in a Chinese Han population: a meta-analysis. Metabolism. 2012;61(8):846-52. doi: 10.1016/j.metabol.2011.10.013.

111. Hou X, Chen X, Shi J. Genetic polymorphism of MTHFR C677T and premature coronary artery disease susceptibility: a meta-analysis. Gene. 2015;563(1):39-44. doi: 10.1016/j.gene.2015.03.062.

112. Xuan C, Bai XY, Gao G, Yang Q, He GW. Association between polymorphism of methylethenehydrolase redutase (MTHFR) C677T and risk of myocardial infarction: a meta-analysis for 8,140 cases and 10,522 controls. Arch Med Res. 2011;42(8):677-85. doi: 10.1177/0140125911430366.

113. Thambirajah J, Townsend JN. Homocysteine and atherothrombosis—mechanisms for injury. Eur Heart J. 2000;21(12):967-74. doi: 10.1093/eurheartj/199.1914.

114. Hasan T, Arora R, Bansal AK, Bhattacharya R, Sharma GS, Singh LR. Disturbed homocysteine metabolism is associated with cancer. Exp Mol Med. 2019;51(2):1-13. doi: 10.1038/s12276-019-0216-4.

115. Bravata V. Controversial roles of methylethenehydrolase redutase polymorphisms and folate in breast cancer risk. Jpn J Food Sci Nutr. 2015;66(1):43-9. doi: 10.3109/09663766.2014.959896.

116. Matsuo K, Hamajima N, Hirai T, Kato T, Inoue M, Takezaki T, et al. Methionine synthase redutase gene A66G polymorphism is associated with risk of colorectal cancer. Asian Pac J Cancer Prev. 2002;3(4):353-9.

117. Krajnovic M, Lamothe S, Labuda D, Lemieux-Blanchard E, Theoret Y, Moghrami A, et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood. 2004;103(3):252-7. doi: 10.1182/blood-2003-06-1794.

118. Singal R, Ferdinand L, Das PM, Reis IM, Schlesselman JJ. Polymorphisms in the methylethenehydrolase redutase gene and prostate cancer risk. Int J Oncol. 2004;25(5):1465-71.

119. Masoomi M, Azedaki N, Shahouzehi B. Elevated plasma homocysteine concentration in opium-addicted individuals. Addict Health. 2015;7(3-4):149-56.

120. Salomaa V, Rasi V, Kulathinal S, Vahtera E, Jauhiainen M, Ehnhelm C, et al. Hemostatic factors as predictors of coronary artery disease events and total mortality: the FINRISK ‘92 Hemostasis Study. Arterioscler Thromb Vasc Biol. 2002;22(2):353-8. doi: 10.1161/01.ATV.01020.104078.

121. De Luca G, Verdoia M, Casseti E, Schaffer A, Cavallino C, Bolzani V, et al. High fibrinogen level is an independent predictor of occurrence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis. 2011;31(4):458-63. doi: 10.1007/s11239-010-0531-z.

122. Devendra GP, Hart SA, Whitney EJ, Krasuski RA. Impact of fibrinogen levels on angiographic progression and 12-year survival in the armed forces regression study. Angiology. 2010;61(4):333-7. doi: 10.1177/0003319709360525.

123. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Fibrinogen levels on angiographic progression and 12-year disease among Italian population. J Thromb Thrombolysis. 2011;31(4):458-63. doi: 10.1016/j.jthroms.2011.03.032.

124. Holzinger D, Danilovic I, Seemann R, Kornek G, Engelmann J, Pillerstorff R, et al. Prognostic impact of pretreatment plasma fibrinogen in patients with locally advanced oral and oropharyngeal cancer. PLoS One. 2016;11(6):e0158697. doi: 10.1371/journal.pone.0158697.

125. Li H, Zhao T, Ji X, Liang S, Wang Z, Yang Y, et al. Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer. Tumour Biol. 2016;37(3):3535-42. doi: 10.1007/s13277-015-4184-6.

126. Ma C, Zhuo Y, Zhou S, Zhao K, Lu B, Sun E. Preoperative peripheral plasma fibrinogen level is an independent prognostic marker in periorbital cancer. Oncol. 2017;87:1235-63. doi: 10.18632/oncotarget.12563.

127. Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 1983;2(11):41-73. doi: 10.1007/BF00046905.

128. Lu DY, Chen XL, Ding J. Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy. Med Hypotheses. 2007;68(1):188-93. doi: 10.1016/j.mehy.2006.06.045.

129. Asgary S, Sarazfzeganeg N, Naderi GA, Rozebhan R. Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter? Lipids Health Dis. 2008;7:42. doi: 10.1186/1476-511x-7-42.

130. Masoomi M, Nasri HR, Farajpour F. Comparison of plasma fibrinogen level in opioid addict men with non-addict men. J Kerman Univ Med Sci. 2002;9(1):27-31. [Persian].

131. Dugtia B, Negiital M, Iqbal F. Glycated hemoglobin (HbA1c) correlation with severity of coronary artery disease in non-diabetic patients-a hospital based study from north-Eastern India. J Clin Diagn Res. 2016;10(9):OC20-OC3. doi: 10.7860/jcdr/2016/22378.8525.

132. Jia EZ, An FH, Chen ZH, Li LH, Mao HW, Li ZY, et al. Hemoglobin A1c risk score for the prediction of coronary artery disease severity in subjects with angiographically diagnosed coronary atherosclerosis. Cell Physiol Biochem. 2014;34(3):672-80. doi: 10.1159/000363032.

133. de Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? Br J Cancer. 2014;110(9):2361-8. doi: 10.1038/bjc.2014.150.

134. Tsai MC, Chen KD, Wang CC, Huang KT, Wu CH, Kuo IY, et al. Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling. Cell Death Discov. 2015;1:15051. doi: 10.1038/cddiscovery.2015.51.

135. Meade TV, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342(8879):1076-9. doi: 10.1016/0140-6736(93)92062-x.

136. Hemborg TA, Swartz GM, Papathanassiau A, Vlasuk GP, Rote WE, Green SJ, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003;63(11):2997-3000.

137. Versteeg HH, Spek CA, Richel DJ, Peppelensb MP. Coagulation factors V and Xa inhibit apoptosis and anoikis. Cell Physiol Biochem. 2014;34(3):672-80. doi: 10.1159/000363032.